Literature DB >> 36042045

CRISPR/Cas9 mediated knocking out of OPN gene enhances radiosensitivity in MDA-MB-231 breast cancer cell line.

Rahil Ghanbarnasab Behbahani1, Amir Danyaei2, Ali Teimoori3, Mohammad Javad Tahmasbi1, Niloofar Neisi4.   

Abstract

PURPOSE: Although chemotherapy and radiotherapy in conjunction with surgery have been known as the standard methods for patients with breast cancer, they frequently face resistance due to the failure of cells to death. Accordingly, improving the results requires discovering novel therapeutic approaches based on the changes in the molecular biology of cancer cells. Osteopontin (OPN) is a secreted protein that previous studies have shown to be associated with progression, poor prognosis, and metastasis in breast cancer. The current study examined the synergistic effects of radiotherapy and knocking out of OPN gene, utilizing CRISPR/Cas9 technique in MDA-MB-231 breast cancer cells.
METHODS: We used to knock out the OPN gene by the two different gRNAs. The cells irradiated 24 h after transfection. The mRNA expression, tumor cell proliferation, cell cycle distribution, growth, and apoptosis were measured. Moreover, activation of Chk1 and AKT were measured via western blot.
RESULTS: We demonstrated the OPN knocking out along with radiation led to the promotion of apoptosis, suppression of downstream genes, reduction of cell viability, and inhibition of cell-cycle progression. The western blot analysis has indicated that the knocking out of the OPN gene along with radiotherapy changes DNA damage responses substantially.
CONCLUSIONS: The OPN gene knocking out with radiotherapy might be an efficient approach to overcome the radioresistance in breast cancer.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Breast cancer; CRISPR; MDA-MB-231 cell line; Osteopontin; Radiotherapy

Year:  2022        PMID: 36042045     DOI: 10.1007/s00432-022-04304-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  21 in total

1.  Clonogenic assay of cells in vitro.

Authors:  Nicolaas A P Franken; Hans M Rodermond; Jan Stap; Jaap Haveman; Chris van Bree
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 2.  Full-length osteopontin and its splice variants as modulators of chemoresistance and radioresistance (Review).

Authors:  Etel R P Gimba; Mariana C M Brum; Gabriela Nestal De Moraes
Journal:  Int J Oncol       Date:  2018-12-06       Impact factor: 5.650

3.  Breast cancer radioresistance may be overcome by osteopontin gene knocking out with CRISPR/Cas9 technique.

Authors:  R G Behbahani; A Danyaei; A Teimoori; N Neisi; M J Tahmasbi
Journal:  Cancer Radiother       Date:  2021-01-07       Impact factor: 1.018

4.  An osteopontin splice variant induces anchorage independence in human breast cancer cells.

Authors:  B He; M Mirza; G F Weber
Journal:  Oncogene       Date:  2006-04-06       Impact factor: 9.867

5.  MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks.

Authors:  Michael Fraser; Shane M Harding; Helen Zhao; Carla Coackley; Daniel Durocher; Robert G Bristow
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

6.  Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma.

Authors:  Amy L Collins; Jonathan Rock; Lavina Malhotra; Wendy L Frankel; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2012-03-30       Impact factor: 5.344

Review 7.  CD44 cell adhesion molecules.

Authors:  S Goodison; V Urquidi; D Tarin
Journal:  Mol Pathol       Date:  1999-08

8.  Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells.

Authors:  J Dai; L Peng; K Fan; H Wang; R Wei; G Ji; J Cai; B Lu; B Li; D Zhang; Y Kang; M Tan; W Qian; Y Guo
Journal:  Oncogene       Date:  2009-07-13       Impact factor: 9.867

9.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

10.  Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.

Authors:  Antje Hahnel; Henri Wichmann; Matthias Kappler; Matthias Kotzsch; Dirk Vordermark; Helge Taubert; Matthias Bache
Journal:  Radiat Oncol       Date:  2010-09-17       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.